The Bydureon Phase lll Trial to Begin Recruiting

The Bydureon Phase lll Trial to Begin Recruiting
Recruitment is starting for the next phase of the Exenatide-PD trial to determine in a larger cohort whether this diabetes treatment (known as a GLP-1 agonist) can slow down disease progression in Parkinson’s. This phase III efficacy trial is the next stage in this programme of trials to determine whether this drug is a beneficial treatment for people with Parkinson's. ... read more
Source: The Cure Parkinson’s TrustPublished on 2019-10-10